Current Size: 100%
Age-specific survival
Cancer | Years | Method | Sex | Age | Survived | Net survival | 95% lower | 95% upper |
---|---|---|---|---|---|---|---|---|
All ex C44 | 2010-2014 | hybrid | Both | 15-44 | 1.00 years | 92.9% | 92.4% | 93.5% |
All ex C44 | 2010-2014 | hybrid | Both | 15-44 | 5.00 years | 82.8% | 82.0% | 83.6% |
All ex C44 | 2010-2014 | hybrid | Both | 15-44 | 10.00 years | 77.7% | 76.7% | 78.6% |
All ex C44 | 2010-2014 | hybrid | Both | 45-54 | 1.00 years | 89.1% | 88.5% | 89.6% |
All ex C44 | 2010-2014 | hybrid | Both | 45-54 | 5.00 years | 75.6% | 74.8% | 76.4% |
All ex C44 | 2010-2014 | hybrid | Both | 45-54 | 10.00 years | 70.2% | 69.2% | 71.1% |
All ex C44 | 2010-2014 | hybrid | Both | 55-64 | 1.00 years | 84.2% | 83.8% | 84.7% |
All ex C44 | 2010-2014 | hybrid | Both | 55-64 | 5.00 years | 69.9% | 69.2% | 70.6% |
All ex C44 | 2010-2014 | hybrid | Both | 55-64 | 10.00 years | 64.5% | 63.7% | 65.3% |
All ex C44 | 2010-2014 | hybrid | Both | 65-74 | 1.00 years | 77.8% | 77.3% | 78.4% |
All ex C44 | 2010-2014 | hybrid | Both | 65-74 | 5.00 years | 62.6% | 61.8% | 63.3% |
All ex C44 | 2010-2014 | hybrid | Both | 65-74 | 10.00 years | 57.2% | 56.3% | 58.2% |
All ex C44 | 2010-2014 | hybrid | Both | 75-99 | 1.00 years | 59.4% | 58.7% | 60.1% |
All ex C44 | 2010-2014 | hybrid | Both | 75-99 | 5.00 years | 41.6% | 40.6% | 42.5% |
All ex C44 | 2010-2014 | hybrid | Both | 75-99 | 10.00 years | 39.0% | 37.2% | 40.8% |